LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/312586

Lähdeviite

Rusanen , J , Toivonen , A , Hepojoki , J , Hepojoki , S , Arikoski , P , Heikkinen , M , Vaarala , O , Ilonen , J & Hedman , K 2019 , ' LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection ' , PLoS One , vol. 14 , no. 11 , e0225851 . https://doi.org/10.1371/journal.pone.0225851

Julkaisun nimi: LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection
Tekijä: Rusanen, Juuso; Toivonen, Anne; Hepojoki, Jussi; Hepojoki, Satu; Arikoski, Pekka; Heikkinen, Markku; Vaarala, Outi; Ilonen, Jorma; Hedman, Klaus
Muu tekijä: University of Helsinki, Medicum
University of Helsinki, HUSLAB
University of Helsinki, Helsinki One Health (HOH)
University of Helsinki, Viral Zoonosis Research Unit
University of Helsinki, HUS Children and Adolescents
University of Helsinki, HUSLAB
Päiväys: 2019-11-29
Kieli: eng
Sivumäärä: 12
Kuuluu julkaisusarjaan: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/312586
Tiivistelmä: The diagnosis of celiac disease (CD) is currently based on serology and intestinal biopsy, with detection of anti-tissue transglutaminase (tTG) IgA antibodies recommended as the first-line test. Emphasizing the increasing importance of serological testing, new guidelines and evidence suggest basing the diagnosis solely on serology without confirmatory biopsy. Enzyme immunoassays (EIAs) are the established approach for anti-tTG antibody detection, with the existing point-of-care (POC) tests lacking sensitivity and/or specificity. Improved POC methods could help reduce the underdiagnosis and diagnostic delay of CD. We have previously developed rapid homogenous immunoassays based on time-resolved Förster resonance energy transfer (TR-FRET), and demonstrated their suitability in serodiagnostics with hanta- and Zika virus infections as models. In this study, we set out to establish a protein L -based TR-FRET assay (LFRET) for the detection of anti-tTG antibodies. We studied 74 patients with biopsy-confirmed CD and 70 healthy controls, with 1) the new tTG-LFRET assay, and for reference 2) a well-established EIA and 3) an existing commercial POC test. IgG depletion was employed to differentiate between anti-tTG IgA and IgG positivity. The sensitivity and specificity of the first-generation tTG-LFRET POC assay in detection of CD were 87.8% and 94.3%, respectively, in line with those of the reference POC test. The sensitivity and specificity of EIA were 95.9% and 91.9%, respectively. This study demonstrates the applicability of LFRET to serological diagnosis of autoimmune diseases in general and of CD in particular.
Avainsanat: 3111 Biomedicine
318 Medical biotechnology
11832 Microbiology and virology
Tekijänoikeustiedot:


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
journal.pone.0225851.pdf 1.666MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot